Training Program in Stem Cell Biology and Engineering
Grant Award Details
Grant Type:
Grant Number:
TG2-01151
Investigator(s):
Award Value:
$2,448,823
Status:
Closed
Progress Reports
Reporting Period:
Year 4
Reporting Period:
Year 5
Reporting Period:
Year 6+NCE
Grant Application Details
Application Title:
Training Program in Stem Cell Biology and Engineering
Public Abstract:
We propose to continue our successful interdisciplinary Training Program in Stem Cell Biology and Engineering (CIRM Type III). The program will educate the next generation of stem cell researchers and provide the ethical background and research skills necessary for them to succeed in this rapidly moving, multifaceted field. The training grant will support research in two broad but interrelated areas: 1. Inquiries into the fundamental molecular biology of stem cell proliferation and differentiation, using powerful methods of modern molecular biology. 2. Bioengineering approaches will be used to develop novel biotechnologies for stem cell research, taking advantage of state of the art research and facilities. Postdoctoral and pre-doctoral trainees will be immersed in a highly interactive and supportive program that facilitates research and instruction in stem cell biology and engineering. Trainees will be involved in groundbreaking research that will solve key problems and help bring stem cell therapies into practice. We will continue very successful courses initiated in the previous funding period, in stem cell biology and stem cell ethics. The training environment will be enriched by seminars from visiting researchers, multiple journal clubs, internal research seminars, video conferencing to collaborating institutions, and attendance at national and international scientific meetings. In the current proposal, we have added additional PIs and expanded the training opportunities for CIRM scholars. Training will be strengthened with participation by CIRM scholars in the CIRM Bridges program with two nearby institutions, to provide mentoring and leadership experience. A new seminar series will be initiated that features novel, interdisciplinary biotechnologies, and instruction will be improved and expanded with new teaching technologies. The training program will be augmented by the considerable investment of the campus, including renovation of new facilities, funding of graduate and postdoctoral activities, and recruitment of new stem cell faculty members.
Statement of Benefit to California:
California, like much of the United States, is facing a staggering challenge to its health care system. A perfect storm of soaring medical costs and the aging of the population augers poorly for the economic future of health care as we know it. Increasingly physicians are treating chronic, debilitating, and therefore expensive diseases with organ specific impairments. The demographic wave of the Baby Boomers will accelerate many of these issues. By 2020 they will average 64 years of age. As a result, the percentage of elderly in California is expected to grow from what was 14 percent in 1990 to 22 percent in 2030. Chronic degenerative diseases, which tend to afflict an aging population, represent a proportionally high percentage of individuals in California. Major innovative approaches are now, more than ever, an imperative. Our stem cell program, with its emphasis on enabling technologies, has the potential to make an impact upon many of these conditions. Degenerative diseases are those diseases caused by the loss or dysfunction of cells. Examples include cardiovascular disease, osteoarthritis, Parkinson’s disease, osteoporosis, diabetes, and macular degeneration. Among these conditions, stem cell work at our institution would leverage a strong existing program in macular degeneration, a condition that is just beginning to be addressed in the stem cell field. However, further research in molecular biology and engineering is needed to bring forward new therapies. There is a great need to train young scientists in stem cell biology and engineering to prime the engine of innovative research. We propose a Type III Training Program to educate the next generation of stem cell researchers, with an interdisciplinary focus on stem cell biology and engineering. This highly interactive mix holds a great deal of promise for the opening of stem biology to the bioengineering community, and the development of materials and devices for the stem cell field. This program will benefit the people and state of California by providing top quality scientific and ethical training to young researchers who will go on to develop cellular therapies for debilitating disease. In addition to the medical potential of stem cells and the spear heading of interdisciplinary work, our program will also bring economic benefits to the state. Multiple collaborations with industry have already emerged from our program in a very short time, stimulating growth of the California biotechnology industry.
Publications
- Biol Chem (2013): Amyloid beta peptide cleavage by kallikrein 7 attenuates fibril growth and rescues neurons from Abeta mediated toxicity in vitro. (PubMed: 23989112)
- Dev Dyn (2010): Caenorhabditis elegans as a model for stem cell biology. (PubMed: 20419785)
- Invest Ophthalmol Vis Sci (2015): Canonical/beta-catenin Wnt pathway activation improves retinal pigmented epithelium derivation from human embryonic stem cells. (PubMed: 25604686)
- Stem Cells (2015): Concise Review: Making Stem Cells Retinal: Methods for Deriving Retinal Pigment Epithelium and Implications for Patients With Ocular Disease. (PubMed: 25809736)
- Nucleic Acids Res (2012): Deep annotation of mouse iso-miR and iso-moR variation. (PubMed: 22434881)
- Stem Cells Transl Med (2015): Defined culture of human embryonic stem cells and xeno-free derivation of retinal pigmented epithelial cells on a novel, synthetic substrate. (PubMed: 25593208)
- Stem Cells (2009): Derivation of functional retinal pigmented epithelium from induced pluripotent stem cells. (PubMed: 19658190)
- J Tissue Eng Regen Med (2012): Differentiation of human pluripotent stem cells to retinal pigmented epithelium in defined conditions using purified extracellular matrix proteins. (PubMed: 22514096)
- Dev Ophthalmol (2014): Differentiation of pluripotent stem cells into retinal pigmented epithelium. (PubMed: 24732763)
- Genes Dev (2012): Essential role for Notch signaling in restricting developmental plasticity. (PubMed: 23124064)
- Cell Stem Cell (2015): Humanized Mice Reveal Differential Immunogenicity of Cells Derived from Autologous Induced Pluripotent Stem Cells. (PubMed: 26299572)
- Anal Chem (2011): Improving Aptamer Selection Efficiency through Volume Dilution, Magnetic Concentration, and Continuous Washing in Microfluidic Channels. (PubMed: 21774453)
- Biomaterials (2015): Light-activated RNA interference in human embryonic stem cells. (PubMed: 26086448)
- Stem Cells (2010): Memory in Induced Pluripotent Stem Cells: Reprogrammed Human Retinal Pigmented Epithelial Cells Show Tendency for Spontaneous Redifferentiation. (PubMed: 20882530)
- Nano Lett (2014): Modular plasmonic nanocarriers for efficient and targeted delivery of cancer-therapeutic siRNA. (PubMed: 24597503)
- Stem Cells (2014): Nrf2, a regulator of the proteasome, controls self-renewal and pluripotency in human embryonic stem cells. (PubMed: 24895273)
- J Cell Physiol (2011): Pluripotent human stem cells for the treatment of retinal disease. (PubMed: 21520078)
- Small (2011): Polymer nanoneedle-mediated intracellular drug delivery. (PubMed: 21695782)
- PLoS One (2009): Protective effects of human iPS-derived retinal pigment epithelium cell transplantation in the retinal dystrophic rat. (PubMed: 19997644)
- Proc Natl Acad Sci U S A (2013): Quantitative selection and parallel characterization of aptamers. (PubMed: 24167271)
- Proc Natl Acad Sci U S A (2010): Quantitative selection of DNA aptamers through microfluidic selection and high-throughput sequencing. (PubMed: 20705898)
- Stem Cells Transl Med (2013): Rapid and Efficient Directed Differentiation of Human Pluripotent Stem Cells Into Retinal Pigmented Epithelium. (PubMed: 23599499)
- Stem Cells Transl Med (2014): Reprogramming Human Retinal Pigmented Epithelial Cells to Neurons Using Recombinant Proteins. (PubMed: 25298373)
- Stem Cells Transl Med (2014): ROCK Inhibition Extends Passage of Pluripotent Stem Cell-Derived Retinal Pigmented Epithelium. (PubMed: 25069775)
- Transl Vis Sci Technol (2016): ROCK Inhibition Promotes Attachment, Proliferation, and Wound Closure in Human Embryonic Stem Cell-Derived Retinal Pigmented Epithelium. (PubMed: 27917311)
- Stem Cells Dev (2010): Roles of integrins in human induced pluripotent stem cell growth on Matrigel and vitronectin. (PubMed: 19811096)
- Proc Natl Acad Sci U S A (2011): Selection of phage-displayed peptides on live adherent cells in microfluidic channels. (PubMed: 21486998)
- J Control Release (2012): Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. (PubMed: 22634092)
- J Biotechnol (2010): Synthetic surfaces for human embryonic stem cell culture. (PubMed: 20132848)
- Development (2013): Transdifferentiation and remodeling of post-embryonic C. elegans cells by a single transcription factor. (PubMed: 24257624)
- Proc Natl Acad Sci U S A (2013): Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. (PubMed: 23754411)